GENE THERAPY FOR NEURONAL CEROID LIPOFUSCINOSES

Provided herein are methods and compositions for treatment of Batten disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5′ inverted terminal repeat (ITR) se...

Full description

Saved in:
Bibliographic Details
Main Authors Kondragunta, Bhargavi, Guibert, Matthieu Pierre, Mercer, Andrew Christopher, Buss, Nicholas Alexander Piers Sascha, Marshall, Tristan James, Stadelman, Robert Thomas, Bee, Jared, Gerner, Franz Michael, DePaz, Roberto, Melethil, Subha Karumuthil, Carrell, Micheal James
Format Patent
LanguageEnglish
Published 23.12.2021
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are methods and compositions for treatment of Batten disease. Such compositions include a recombinant adeno-associated virus (rAAV), said rAAV comprising an AAV capsid, and a vector genome packaged therein, said vector genome comprising (a) an AAV 5′ inverted terminal repeat (ITR) sequence; (b) a promoter; (c) a CLN2 coding sequence encoding a human TPP1; (d) an AAV 3′ ITR. Also provided herein are methods of treating Batten disease comprising administering to a subject in need thereof the rAAV described herein via more than one route. Also provide herein are pharmaceutical compositions comprising the rAAV described herein and related methods of treating Batten disease.
Bibliography:Application Number: US201917292750